Vor Biopharma Inc. (NASDAQ:VOR) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $41.71.

VOR has been the subject of several analyst reports. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Wedbush increased their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently bought and sold shares of VOR. Engineers Gate Manager LP grew its position in Vor Biopharma by 37.5% during the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after buying an additional 10,071 shares during the period. Cannon Global Investment Management LLC bought a new stake in Vor Biopharma in the first quarter worth about $209,000. Sei Investments Co. bought a new stake in Vor Biopharma in the first quarter worth about $245,000. Independent Financial Group LLC purchased a new position in Vor Biopharma in the first quarter valued at about $249,000. Finally, Bollard Group LLC boosted its stake in Vor Biopharma by 763.8% in the fourth quarter. Bollard Group LLC now owns 23,987 shares of the company’s stock valued at $314,000 after acquiring an additional 21,210 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Price Performance

VOR stock opened at $18.69 on Monday. The company’s 50-day moving average is $22.09 and its 200-day moving average is $18.00. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $39.49.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, equities analysts predict that Vor Biopharma will post -2.56 EPS for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.